215 related articles for article (PubMed ID: 35145298)
1. PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity.
Sugiura D; Okazaki IM; Maeda TK; Maruhashi T; Shimizu K; Arakaki R; Takemoto T; Ishimaru N; Okazaki T
Nat Immunol; 2022 Mar; 23(3):399-410. PubMed ID: 35145298
[TBL] [Abstract][Full Text] [Related]
2. Restriction of PD-1 function by
Sugiura D; Maruhashi T; Okazaki IM; Shimizu K; Maeda TK; Takemoto T; Okazaki T
Science; 2019 May; 364(6440):558-566. PubMed ID: 31000591
[TBL] [Abstract][Full Text] [Related]
3. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.
Zhao Y; Lee CK; Lin CH; Gassen RB; Xu X; Huang Z; Xiao C; Bonorino C; Lu LF; Bui JD; Hui E
Immunity; 2019 Dec; 51(6):1059-1073.e9. PubMed ID: 31757674
[TBL] [Abstract][Full Text] [Related]
4. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
5. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.
Tekguc M; Wing JB; Osaki M; Long J; Sakaguchi S
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301886
[TBL] [Abstract][Full Text] [Related]
6. Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity.
Zhang Y; Song Q; Cassady K; Lee M; Tang H; Zheng M; Wang B; Schones DE; Fu YX; Riggs AD; Martin PJ; Feng R; Zeng D
Proc Natl Acad Sci U S A; 2023 Apr; 120(16):e2205085120. PubMed ID: 37036990
[TBL] [Abstract][Full Text] [Related]
7. The CTLA-4 immune checkpoint protein regulates PD-L1:PD-1 interaction via transendocytosis of its ligand CD80.
Kennedy A; Robinson MA; Hinze C; Waters E; Williams C; Halliday N; Dovedi S; Sansom DM
EMBO J; 2023 Mar; 42(5):e111556. PubMed ID: 36727298
[TBL] [Abstract][Full Text] [Related]
8. Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes.
Horn LA; Long TM; Atkinson R; Clements V; Ostrand-Rosenberg S
Cancer Immunol Res; 2018 Jan; 6(1):59-68. PubMed ID: 29122838
[TBL] [Abstract][Full Text] [Related]
9. Identification, binding, and structural characterization of single domain anti-PD-L1 antibodies inhibitory of immune regulatory proteins PD-1 and CD80.
Kang-Pettinger T; Walker K; Brown R; Cowan R; Wright H; Baravalle R; Waters LC; Muskett FW; Bowler MW; Sawmynaden K; Coombs PJ; Carr MD; Hall G
J Biol Chem; 2023 Jan; 299(1):102769. PubMed ID: 36470427
[TBL] [Abstract][Full Text] [Related]
10. A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation.
Haile ST; Horn LA; Ostrand-Rosenberg S
Cancer Immunol Res; 2014 Jul; 2(7):610-5. PubMed ID: 24819296
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 Binds to B7-1 Only
Chaudhri A; Xiao Y; Klee AN; Wang X; Zhu B; Freeman GJ
Cancer Immunol Res; 2018 Aug; 6(8):921-929. PubMed ID: 29871885
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration.
Piao W; Li L; Saxena V; Iyyathurai J; Lakhan R; Zhang Y; Lape IT; Paluskievicz C; Hippen KL; Lee Y; Silverman E; Shirkey MW; Riella LV; Blazar BR; Bromberg JS
Nat Commun; 2022 Apr; 13(1):2176. PubMed ID: 35449134
[TBL] [Abstract][Full Text] [Related]
13. CD80 Expressed by CD8
Rollins MR; Gibbons Johnson RM
J Immunol Res; 2017; 2017():7659462. PubMed ID: 29181416
[TBL] [Abstract][Full Text] [Related]
14. A missing PD-L1/PD-1 coinhibition regulates diabetes induction by preproinsulin-specific CD8 T-cells in an epitope-specific manner.
Schuster C; Brosi H; Stifter K; Boehm BO; Schirmbeck R
PLoS One; 2013; 8(8):e71746. PubMed ID: 23977133
[TBL] [Abstract][Full Text] [Related]
15. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.
Paterson AM; Brown KE; Keir ME; Vanguri VK; Riella LV; Chandraker A; Sayegh MH; Blazar BR; Freeman GJ; Sharpe AH
J Immunol; 2011 Aug; 187(3):1097-105. PubMed ID: 21697456
[TBL] [Abstract][Full Text] [Related]
16. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
17. Separation anxiety: Splitting PD-L1 from CD80 suppresses autoimmunity.
Bracey NA; Maltzman JS
Sci Immunol; 2022 Apr; 7(70):eabq1728. PubMed ID: 35363545
[TBL] [Abstract][Full Text] [Related]
18. PD-1/CD80
Zhang LZ; Yang JG; Chen GL; Xie QH; Fu QY; Xia HF; Li YC; Huang J; Li Y; Wu M; Liu HM; Wang FB; Yi KZ; Jiang HG; Zhou FX; Wang W; Yu ZL; Zhang W; Zhong YH; Bian Z; Yang HY; Liu B; Chen G
Nat Commun; 2024 May; 15(1):3884. PubMed ID: 38719909
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1.
Bodhankar S; Chen Y; Vandenbark AA; Murphy SJ; Offner H
J Neuroinflammation; 2013 Sep; 10():111. PubMed ID: 24015822
[TBL] [Abstract][Full Text] [Related]
20. Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes.
Afroj T; Mitsuhashi A; Ogino H; Saijo A; Otsuka K; Yoneda H; Tobiume M; Nguyen NT; Goto H; Koyama K; Sugimoto M; Kondoh O; Nokihara H; Nishioka Y
J Immunol; 2021 Mar; 206(6):1204-1214. PubMed ID: 33504617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
